Stratec Biomedical AG (SBS) Given Consensus Rating of “Hold” by Analysts

Shares of Stratec Biomedical AG (ETR:SBS) have been given an average recommendation of “Hold” by the six research firms that are covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is €61.50 ($75.93).

SBS has been the topic of several research analyst reports. Warburg Research set a €62.00 ($76.54) price objective on shares of Stratec Biomedical and gave the stock a “buy” rating in a research report on Thursday, October 26th. Deutsche Bank set a €56.00 ($69.14) price objective on shares of Stratec Biomedical and gave the stock a “neutral” rating in a research report on Tuesday, October 24th. Kepler Capital Markets set a €70.00 ($86.42) price objective on shares of Stratec Biomedical and gave the stock a “buy” rating in a research report on Friday, October 27th. Berenberg Bank set a €59.00 ($72.84) price objective on shares of Stratec Biomedical and gave the stock a “neutral” rating in a research report on Monday, October 30th. Finally, Oddo Bhf set a €58.00 ($71.60) price target on shares of Stratec Biomedical and gave the company a “neutral” rating in a research report on Monday, October 23rd.

Stratec Biomedical (ETR:SBS) opened at €71.10 ($87.78) on Wednesday. The firm has a market cap of $854.73 and a P/E ratio of 31.05. Stratec Biomedical has a 52-week low of €45.67 ($56.38) and a 52-week high of €73.40 ($90.62).

TRADEMARK VIOLATION NOTICE: “Stratec Biomedical AG (SBS) Given Consensus Rating of “Hold” by Analysts” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/31/stratec-biomedical-ag-sbs-given-consensus-rating-of-hold-by-analysts.html.

About Stratec Biomedical

STRATEC Biomedical AG designs and manufactures solutions for automated processes in the fields of in vitro diagnostics and life sciences. The company operates through two segments, Instrumentation and All Other segments. It offers instrumentation products, such as automated analyzer systems, including THOLOS VMI-100, GEMINI, and GEMINI Combo for use in clinical diagnostics and biotechnology to laboratories, blood banks, and research institutes.

Analyst Recommendations for Stratec Biomedical (ETR:SBS)

Receive News & Ratings for Stratec Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stratec Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply